PHILADELPHIA — (Jan. 17, 2022) — A new study by researchers at The Wistar Institute , an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, has identified a new potential pathway for developing therapeutics that target Epstein-Barr virus ( EBV ). They discovered that the way the EBV genome folds, and thereby expresses itself and causes disease, is more complex than researchers originally thought, and they identified molecules that could be targeted to disrupt this folding.
Jubilant Therapeutics, a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, has announced a collaboration with biomedical research non-profit The Wistar Institute to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors to reduce the clinical severity of COVID-19.